Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2017 Feb 1.
Published in final edited form as: Ann Neurol. 2016 Jan 19;79(2):331. doi: 10.1002/ana.24581

Rare variants in MC1R/TUBB3 exon 1 are not associated with Parkinson’s disease

Oswaldo Lorenzo-Betancor 1,*, Zbigniew K Wszolek 2, Owen A Ross 1
PMCID: PMC4755887  NIHMSID: NIHMS746220  PMID: 26677074

Tell-Marti and colleagues recently published a variant (rs1805008; p.R160W) in the melanocortin 1 receptor (MC1R) gene associated with an increased risk of Parkinson’s disease (PD) in a Spanish series1. According to ExAC Browser (http://exac.broadinstitute.org/) this variant is a common variant in non-Finnish Europeans (Minor allele frequency; MAF = 0.08) and it may help explain the previous associations establishing that PD patients have an increased risk of developing melanoma2. Interestingly, the single exon of MC1R gene overlaps the first exon of the tubulin, beta 3 class III (TUBB3) gene. The TUBB3 protein is the main component of microtubules3 and therefore may be a more plausible candidate to be involved in PD than MC1R.

We sequenced the MC1R gene (TUBB3 exon 1) to identify variants in our PD patient-control series of 889 PD cases (age = 68.30±11.11 years, age at onset = 62.39±13.08 years, 36.56% females) and 940 healthy controls (age = 65.03±12.74 years, 57.67% females). All subjects included in the study are unrelated, non-Hispanic Caucasians recruited at Mayo Clinic, Jacksonville. We found 37 nonsynonymous variants in MC1R/TUBB3 exon 1 that were split into 29 missense, 4 frameshift, 3 stop mutations and 1 inframe insertion; thirty variants had a MAF<0.01 (Supplementary Table 1).

None of the variants, including the reported p.R160W substitution, showed a statistically significant association with PD after Bonferroni correction (Supplementary Table 1). Gene burden test analysis taking into account only rare variants (MAF<1%) did not show an increase frequency of rare variants in cases in comparison with controls either (data not shown). These findings support a meta-analysis4 and a genotyping study5 which also failed to replicate the association between PD and variants in MC1R.

From our data, the replication studies and polymorphic nature of the MC1R gene it is unlikely that variation alters the individual susceptibility to PD. However, the genomic overlap with TUBB3 could indicate biological relevance to the region. In addition, 100kb upstream from MC1R gene is located Transcription factor 25 (TCF25), which has been reported to be a leucine-rich repeat kinase 2 (LRRK2) interactor6. A reanalysis of TUBB3 exons 2 to 5 and the TCF25 gene, which are highly conserved, may be warranted in the original Spanish series to exclude linked variants in these genes. As the number of PD exomes that are available to study increases genomic regions of interest including candidate genes such as this may well be worth a second look.

Supplementary Material

Supp Table S1

Acknowledgements

We wish to thank the patients and families who participated in the study. This work is supported in part by a Morris K. Udall Parkinson's Disease Research Center of Excellence (NINDS P50 #NS072187) and NINDS R01 NS078086.

Footnotes

Potential Conflicts of Interest

There are no conflicts of interest.

REFERENCES

  • 1.Tell-Marti G, Puig-Butille JA, Potrony M, et al. The MC1R melanoma risk variant p.R160W is associated with Parkinson disease. Ann Neurol. 2015 May;77(5):889–894. doi: 10.1002/ana.24373. [DOI] [PubMed] [Google Scholar]
  • 2.Liu R, Gao X, Lu Y, Chen H. Meta-analysis of the relationship between Parkinson disease and melanoma. Neurology. 2011 Jun 7;76(23):2002–2009. doi: 10.1212/WNL.0b013e31821e554e. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Ranganathan S, Dexter DW, Benetatos CA, Hudes GR. Cloning and sequencing of human betaIII-tubulin cDNA: induction of betaIII isotype in human prostate carcinoma cells by acute exposure to antimicrotubule agents. Biochim Biophys Acta. 1998 Jan 21;1395(2):237–245. doi: 10.1016/s0167-4781(97)00168-1. [DOI] [PubMed] [Google Scholar]
  • 4.Dong J, Gao J, Nalls M, et al. Susceptibility loci for pigmentation and melanoma in relation to Parkinson's disease. Neurobiol Aging. 2014 Jun;35(6):1512 e5–1512 e10. doi: 10.1016/j.neurobiolaging.2013.12.020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Lubbe SJ, Escott-Price V, Brice A, et al. Is the MC1R variant p.R160W associated with Parkinson's? Ann Neurol. 2015 Sep 21; doi: 10.1002/ana.24527. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Reyniers L, Del Giudice MG, Civiero L, et al. Differential protein-protein interactions of LRRK1 and LRRK2 indicate roles in distinct cellular signaling pathways. J Neurochem. 2014 Oct;131(2):239–250. doi: 10.1111/jnc.12798. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supp Table S1

RESOURCES